---
title: "Oculis Holding (OCS) Gets a Buy from Chardan Capital"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286050868.md"
description: "Chardan Capital analyst Daniil Gataulin has reiterated a Buy rating on Oculis Holding (OCS) with a price target of $53.00. Gataulin, a 4-star analyst with a 12.3% average return, suggests a Strong Buy consensus for Oculis, which has an average price target of $51.00. He focuses on the Healthcare sector, covering stocks like uniQure and EyePoint Pharmaceuticals."
datetime: "2026-05-12T06:55:57.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286050868.md)
  - [en](https://longbridge.com/en/news/286050868.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286050868.md)
generator: "portal-rs"
---

# Oculis Holding (OCS) Gets a Buy from Chardan Capital

Chardan Capital analyst Daniil Gataulin reiterated a Buy rating on Oculis Holding today and set a price target of $53.00.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

According to TipRanks, Gataulin is a 4-star analyst with an average return of 12.3% and a 42.37% success rate. Gataulin covers the Healthcare sector, focusing on stocks such as uniQure, EyePoint Pharmaceuticals, and Ocular Therapeutix.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Oculis Holding with a $51.00 average price target.

### Related Stocks

- [OCS.US](https://longbridge.com/en/quote/OCS.US.md)
- [OCSAW.US](https://longbridge.com/en/quote/OCSAW.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [XHE.US](https://longbridge.com/en/quote/XHE.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [IHI.US](https://longbridge.com/en/quote/IHI.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [OCUL.US](https://longbridge.com/en/quote/OCUL.US.md)
- [QURE.US](https://longbridge.com/en/quote/QURE.US.md)
- [EYPT.US](https://longbridge.com/en/quote/EYPT.US.md)

## Related News & Research

- [Oculis Reports New Phase 2 ACUITY Biomarker Data Further Supporting Privosegtor’s Neuroprotective Potential in Optic Neuritis | OCS Stock News](https://longbridge.com/en/news/302657914.md)
- [Oculis reports Phase 2 biomarker data supporting Privosegtor’s neuroprotective potential in optic neuritis](https://longbridge.com/en/news/302656484.md)
- [Oculis Holding AG (NASDAQ:OCS) Given Consensus Rating of "Moderate Buy" by Analysts](https://longbridge.com/en/news/299446329.md)
- [Oculis says PREDICT-1 dry eye trial of licaminlimab targets topline data around year-end](https://longbridge.com/en/news/301105050.md)
- [This week in charts: What’s driving biotech’s recent pullback?](https://longbridge.com/en/news/301608695.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**